Innovative ECG Technology VivaQuant's proprietary MDSPTM technology offers highly sensitive and noise-free ECG analysis, making it an attractive solution for pharmaceutical companies and medical device manufacturers seeking accurate cardiac data for drug safety and diagnostics.

Growing Product Portfolio The launch of products like the RX-1 mini and ECG analysis software demonstrates ongoing innovation, providing opportunities to target research institutions, clinical laboratories, and biotech firms interested in advanced cardiac monitoring tools.

Recognition & Validation Awards including the 2021 Tekne Awards and a US patent highlight the company's technological leadership, helping to build credibility and support sales efforts within competitive biomedical markets.

Market Expansion Potential With a focus on cardiac rhythm research and ambulatory ECG analysis, VivaQuant has scope to expand into emerging markets such as wearable health tech and remote patient monitoring, appealing to healthcare providers and telemedicine platforms.

Strategic Partnerships VivaQuant's cloud-based infrastructure and focus on biomedical research position it well for collaboration with pharmaceutical companies, research organizations, and technology integrators aiming to incorporate precise ECG analysis into their workflows.